ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,011.12
-0.22%
US Tech 100
16,908.80
-0.73%
Dow Jones
37,775.38
0.06%
Brent Oil
86.415
-0.66%
Bitcoin
63,568.29
3.73%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BioCryst Pharmaceuticals Inc (BCRX)

  7. BioCryst Pharmaceuticals Inc (BCRX) News

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc (BCRX)

NASDAQ
4.50
-0.08
(-1.75%)
At close: April 18 4:00PM
Delayed by 15 minutes
4.49
-0.09
( -1.97% )
After Hours: 7:07PM
Delayed by 15 minutes

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

BCRX News

Official News Only

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 04 2024
BCRX (-1.75%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 04 2024
BCRX (-1.75%)

Form 8-K - Current report
Edgar (US Regulatory)
February 26 2024
BCRX (-1.75%)

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Edgar (US Regulatory)
February 14 2024
BCRX (-1.75%)

BCRX Discussion

View Posts
Monksdream Monksdream 3 weeks ago
BCRX under $10
👍️0
Monksdream Monksdream 2 months ago
BCRX 10Q 2/26
👍️0
Calcumad Calcumad 3 months ago
It is turning around. Just let the big guys manipulate it enough so they can collect from the shorting and then buy cheaper
👍️0
james kent james kent 8 months ago
when will it turn around?
👍️0
james kent james kent 8 months ago
when will it turn around?
👍️0
ttubular ttubular 1 year ago
Huge buys in AH
👍️0
VivaLasVegas VivaLasVegas 1 year ago
Why is this symbol now taking a digger with all the rest?
What did Stoney do or not do?
👍️0
ttubular ttubular 2 years ago
6:58a ET 8/4/2022 - Globe Newswire
BioCryst Resumes Enrollment in BCX9930 Clinical Program
Mentioned: BCRX
EQNX::TICKER_START (NASDAQ:BCRX), EQNX::TICKER_END BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

Clinical evidence and recent laboratory studies have informed the company's hypothesis that crystals form in the kidneys of some patients. The company believes that lowering the dose to 400 mg and ensuring adequate hydration will dilute the concentration of drug in the urine below the threshold where crystals can form.
👍️0
rosemountbomber rosemountbomber 2 years ago
Don’t have the link but apparently Denner sold a bunch of BCRX 05/16/2022.
👍️0
conix conix 2 years ago
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by stock analysts at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Monday, The Fly reports. They presently have a $13.00 price target on the biotechnology company’s stock, down from their previous price target of $22.00. Barclays‘s price objective suggests a potential upside of 14.14% from the stock’s current price.

BCRX has been the subject of a number of other research reports. Piper Sandler restated an “in-line” rating and issued a $24.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 23rd. Evercore ISI lowered their target price on shares of BioCryst Pharmaceuticals from $25.00 to $15.00 in a research note on Friday, April 8th. StockNews.com assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 24th. Finally, Oppenheimer lowered their target price on shares of BioCryst Pharmaceuticals from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, April 11th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $19.09.
👍️0
Cosa Cosa 2 years ago
I guess it was perfect timing in a way...
👍️0
Cosa Cosa 2 years ago
I reduced my position here to buy more AUPH (facepalm)
👍️0
starkd748 starkd748 2 years ago
13.90s pullback yesss
👍️0
starkd748 starkd748 2 years ago
Overbought pullback in progress TA saves money
👍️0
Limey42 Limey42 2 years ago
You were saying? LMFAO!!!!!!!!
👍️0
game7alcs game7alcs 2 years ago
BCRX just on CNBC for large call volume action
👍️0
starkd748 starkd748 2 years ago
Burnt to a crisp rsi enjoy
👍️0
starkd748 starkd748 2 years ago
Lmfao the rsi is 100 pullback in progress
👍️0
ttubular ttubular 2 years ago
Understatement
👍️0
Limey42 Limey42 2 years ago
This company is a juggernaut!
👍️0
plexrec plexrec 2 years ago
Worldwide addressable market ??? Any estimate what kind of sales company is targeting ??? Totals ???? Rare diseases etc ????? TIA
👍️0
ezyE ezyE 2 years ago
Great buying opportunity.
Shouldn't be this low.
👍️0
easyrider1 easyrider1 2 years ago
What a complete manipulation to knock this down to get cheap stock. IMHO, the best low priced play in the market. The earnings report wil get this th $18 Total disregard for upgrades etc. this is a buying opportunity.
👍️0
easyrider1 easyrider1 2 years ago
Total joke to knock this down under $15 with all the positive news in the short term. Cashing in my soda bottles to buy more
👍️0
starkd748 starkd748 3 years ago
Might buy some options here
👍️0
easyrider1 easyrider1 3 years ago
Strongest day since the ill fated secondary announcement and we held most of the gains. Now we need volume.
👍️0
MZlu MZlu 3 years ago
I remember in recent weeks, we have seen some PR operations which I don't know if they were initiated by BioCryst:
- They won a prize for R&D
- They won a prize for marketing
- Barron's did a favorable mention of the Company
Looks like the big boys are shifting the narrative.
👍️0
easyrider1 easyrider1 3 years ago
First sign of life….someone realizes that this a buy
👍️0
Deano361 Deano361 3 years ago
Yeah been 18 months now and holding for me . I thin pnh results soon will help us
👍️0
easyrider1 easyrider1 3 years ago
I can’t believe that we are trending downward and broke $14. I keep buying a tad on each dip, but the dips are getting lower. I don’t understand what I’m missing with the breakout sales and potential for nearing profitability and real potential for a buyout.

This is still one of my favorite holdings but so disappointing since the Mgmt’s botched secondary attempt and lack of credible explanation.
👍️0
Deano361 Deano361 3 years ago
Yes two positive things going on . The new drug getting approvals and revenue and the pnh upcoming fast track trials
👍️0
Cosa Cosa 3 years ago
The sharp increase in revenue is what got my attention!
👍️0
Cosa Cosa 3 years ago
"Facepalm" I jinxed you guys.
👍️0
bhulkupk bhulkupk 3 years ago
Hi Cosa, welcome…
👍️0
Deano361 Deano361 3 years ago
Hi, been in since March/april 2020 from $3s. The key to this stock are upcoming 4Q results from PNH. PNH positive data makes this a $100 stock in 18 months IMO. Keep an eye on warrants and data.
👍️0
Cosa Cosa 3 years ago
Hello All, new here. Grabbed a little just to have in my portfolio to keep an eye on this. Looks like its been consolidating for almost 5 months! Still doing DD.
👍️0
easyrider1 easyrider1 3 years ago
Can’t believe with all the recent news especially appointment of Galson to the board and connections with Amgen that we’re not at $20 by now. The dip to the low $14’s was a gift.

More publications are suggesting that Bcrx is one off the best stock pics of the year. This is my favorite stock as I continue to accumulate…..doesn’t seem like there is anything but strong upside
👍️0
Deano361 Deano361 3 years ago
Well, it’s one of my few long 3 year stocks IMO . Started at $3 last year
👍️0
bhulkupk bhulkupk 3 years ago
Oh okay, so I can buy some for long term? Thanks in advance.
👍️0
Deano361 Deano361 3 years ago
It’s a quote from executive and it’s all about pnh for the future . Pnh is going to be Golden !!
👍️0
bhulkupk bhulkupk 3 years ago
How?
👍️0
Limey42 Limey42 3 years ago
Embarrassment of riches!
👍️0
MZlu MZlu 3 years ago
I think it is a public show of the poison pill clause. There may have been a potential buyer who wanted to play hard ball but got cock-blocked by Jon "Biochad" Stonehouse.
👍️0
easyrider1 easyrider1 3 years ago
Totally agree. No one saw secondary offering coming after upbeat ER. No one ever saw another offer being pulled. Company owes us a true explanation re timing and intent
👍️0
Limey42 Limey42 3 years ago
Some crazy shit Stoney pulled off today!!!
👍️0
easyrider1 easyrider1 3 years ago
Today showed power of shorts…dropping share price to about $15 after incredible Q2. Proved to be a gift for all and total manipulation. Bought more at $15.40 when I thought I would be lucky to pick up some At $17.50

Nothing is guaranteed, but Bcrx upward move is as close to a certainty as there is in the market. Today was a heck of an opportunity for those with faith. This is an entirely new company.
👍️0
easyrider1 easyrider1 3 years ago
I believe $30 per share and likely a buyout imho
👍️0
ttubular ttubular 3 years ago
Well into triple digits in 2022-2024
👍️0
amonoy1992 amonoy1992 3 years ago
This a solid play? Price predictions here for the next year?
👍️0
easyrider1 easyrider1 3 years ago
The daily dips under $17, set us up for a nice upside after earnings report. I think we are going to surprise a d surpass expectations. Thinking we touch $20 after ER
👍️0

Your Recent History

NASDAQ
BCRX
BioCryst Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved